Takei Y, Minato K, Tsuchiya S, Takise A, Nakano H, Ezawa K, Fueki N, Hoshino H, Naruse I, Nomoto T, Makimoto T, Ishihara S, Saito R, Mori M
First Department of Internal Medicine, Gunma University School of Medicine, National Nishi-Gunma Hospital, Japan.
Oncology. 1997 Jan-Feb;54(1):43-7. doi: 10.1159/000227660.
CYFRA 21-1 is a new tumor marker using two different monoclonal antibodies which recognize the divergent epitope on the N- or C-terminal region of domain 2 of cytokeratin 19 fragment, respectively. In this study, we investigated the relationship between levels of CYFRA 21-1 and survival duration, as well as the efficacy of chemotherapy associated with changes in CYFRA 21-1. Serum samples were obtained from 87 patients with nonoperable lung cancer (35 cases with squamous-cell carcinoma, 33 with adenocarcinoma, 3 with large-cell carcinoma, and 16 with small-cell carcinoma). The cutoff point was set at 3.5 ng/ml. In a CYFRA 21-1 assay, significantly more patients with squamous-cell carcinoma and adenocarcinoma were positive compared to patients with small-cell and large-cell carcinomas (p = 0.0017). Following chemotherapy, blood levels of CYFRA 21-1 decreased significantly in responders versus nonresponders (p = 0.0246). A significant correlation was noted between survival periods and pretreatment levels of CYFRA 21-1 (p = 0.0036). The present study suggests that CYFRA 21-1 might be useful as a possible indicator of survival and therapeutic effect for lung cancer.
细胞角蛋白19片段抗原决定簇21-1（CYFRA 21-1）是一种新型肿瘤标志物，它使用两种不同的单克隆抗体，分别识别细胞角蛋白19片段第2结构域N端或C端区域上不同的表位。在本研究中，我们调查了CYFRA 21-1水平与生存期之间的关系，以及与CYFRA 21-1变化相关的化疗疗效。从87例无法手术的肺癌患者中获取血清样本（35例鳞状细胞癌、33例腺癌、3例大细胞癌和16例小细胞癌）。临界值设定为3.5 ng/ml。在CYFRA 21-1检测中，与小细胞癌和大细胞癌患者相比，鳞状细胞癌和腺癌患者呈阳性的比例显著更高（p = 0.0017）。化疗后，有反应者与无反应者相比，CYFRA 21-1的血液水平显著下降（p = 0.0246）。生存期与CYFRA 21-1治疗前水平之间存在显著相关性（p = 0.0036）。本研究表明，CYFRA 21-1可能作为肺癌生存和治疗效果的一个潜在指标。
